Search results for "Administration"

showing 10 items of 5106 documents

Swelling of the buccal cheek: an unusual presentation of primary tuberculosis.

2007

AdultDNA BacterialMalePathologymedicine.medical_specialtyTuberculosisFistulaOral cavityMycobacteriumDiagnosis DifferentialmedicineHumansTuberculosis CutaneousPrimary tuberculosisbusiness.industryBuccal administrationCheekmedicine.diseaseDermatologymedicine.anatomical_structureCheekOtorhinolaryngologySurgeryOral SurgerySwellingmedicine.symptomPresentation (obstetrics)businessMouth DiseasesTuberculosis OralJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients.

1995

In a significant number of patients affected by the irritable bowel syndrome, an adverse reaction to food is proposed to be a causative factor. A diet that eliminates the offending foods is the obvious treatment for such adverse reactions. Compliance with a dietetic regimen is often poor and sometimes not completely free from risks.Since the diarrheic type of irritable bowel syndrome seems mainly affected by food intolerance, and previous observations suggested that oral cromolyn sodium is effective in such patients, a multicenter therapeutic trial in the diarrheic type of irritable bowel syndrome was carried out in 346 of 409 patients with this disease, to evaluate the effects of oral crom…

AdultDiarrheaMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdministration OralColonic Diseases FunctionalGastroenterologyOral administrationInternal medicineElimination dietAnti-Allergic AgentsCromolyn SodiummedicineHumansAdverse effectIrritable bowel syndromeAgedAged 80 and overChemotherapybusiness.industrydigestive oral and skin physiologyGastroenterologyCromolyn SodiumMiddle Agedmedicine.diseasePrognosisDiarrheaTreatment OutcomeMulticenter studyFemalemedicine.symptombusinessFood HypersensitivityScandinavian journal of gastroenterology
researchProduct

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease

2007

Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a max…

AdultDiarrheaMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsAdolescentCmaxGraft vs Host DiseaseOpportunistic InfectionsGastroenterologySex FactorsDouble-Blind MethodPharmacokineticsOral administrationInternal medicinemedicineHumansTransplantation HomologousPharmacology (medical)MycosisAgedbusiness.industryBody WeightRacial GroupsAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesAcute DiseaseChronic DiseaseFemalebusinessFluconazolemedicine.drugPharmacotherapy
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Preliminary experience with the application of Gadolinium-DTPA before MR imaging-guided laser-induced interstitial thermotherapy of brain tumors

1997

The purpose of this study was to investigate the potential value of i.v. gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) applied before MRI-guided laser-induced interstitial thermotherapy (LITT) of brain tumors without original enhancement, especially in defining total lesion size during therapy. MRI-guided LITT was performed on two patients with astrocytoma WHO II. For both patients, Gd-DTPA was administered intravenously after a first irradiation period and LITT was continued after pulling back the light guide to coagulate the upper parts of the tumor. In both patients, the whole irreversible damaged zone of the second irradiation period after Gd-DTPA showed an intense increase …

AdultGadolinium DTPAMalePathologymedicine.medical_specialtySpatial expansionGadoliniumchemistry.chemical_elementAstrocytomaDrug Administration ScheduleLesionGadolinium DTPAOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingBrain Neoplasmsbusiness.industryAstrocytomaLight guideHyperthermia InducedPentetic AcidImage Enhancementmedicine.diseaseMagnetic Resonance ImagingMr imagingchemistryFemaleLaser TherapySignal intensitymedicine.symptomNuclear medicinebusinessFollow-Up StudiesJournal of Magnetic Resonance Imaging
researchProduct

Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration.

2008

Introduction and Objectives. Primary graft dysfunction (PGD) following lung transplantation (LT) is associated with an activation of the inflammatory cascade and release of cytokines. Inhaled nitric oxide (iNO) provides specific pulmonary vasodilatation and improves oxygenation. Our objective was to verify whether administering iNO to LT patients modified the blood and bronchoalveolar lavage (BAL) interleukin (IL)-6 and -8 levels in the event of PGD. Materials and Methods. Thirty-two LT patients were randomized to the iNO treatment or the control group. Patients in the first group were given 10 ppm of iNO from the start of LT until 48 hours afterward. BAL and peripheral arterial blood sampl…

AdultGraft Rejectionmedicine.medical_specialtyAdolescentmedicine.medical_treatmentNitric OxideGastroenterologyNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsInternal medicineAdministration InhalationmedicineLung transplantationHumansInterleukin 6AgedInflammationTransplantationLungmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Interleukin-8Interleukinrespiratory systemMiddle AgedBronchodilator AgentsTransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiabiology.proteinArterial bloodSurgerybusinessLung TransplantationTransplantation proceedings
researchProduct

Treatment of Vaginal Trichomoniasis with a Single Dose of Tinidazole

1974

SummaryTwenty-two patients with proven vaginal trichomoniasis were treated with a single dose of 2 g. tinidazole. Twenty-one patients were cured, at both the early and the late follow-up visits. No side-effects were noted and no abnormalities of the clinical laboratory parameters were found in the trial. A historical comparison with published works was carried out and the results compared favourably with those found in the literature for tinidazole as well as for other agents used in a similar fashion.

AdultGynecologymedicine.medical_specialtyDose-Response Relationship Drugbusiness.industryVaginal trichomoniasisAdministration OralAntitrichomonal AgentsGeneral MedicineMiddle AgedTrichomonal VaginitisDermatologyTinidazoleAntitrichomonal agentchemistry.chemical_compoundchemistryNitroimidazolesmedicineHumansFemaleTrichomonas Vaginitisbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial

2016

Background Preterm delivery is a leading cause of neonatal morbidity and death. It often results from chorioamnionitis, which is a complication of bacterial vaginosis. Probiotics are effective in the treatment of bacterial vaginosis in women who were not pregnant; studies in pregnant woman are missing. Objective The purpose of this study was to evaluate whether an oral probiotic food supplement supports the maintenance or restoration of a normal vaginal microbiota during pregnancy. Study Design We conducted a randomized, placebo-controlled, triple-blind, parallel group trial. Oral Lactobacillus rhamnosus GR-1and L reuteri RC-14 (10 9 colony-forming units) or placebo were administered for 8 …

AdultLimosilactobacillus reuterimedicine.medical_specialtyAdministration OralChorioamnionitisPlacebolaw.inventionYoung Adult03 medical and health sciencesProbiotic0302 clinical medicineLactobacillus rhamnosusRandomized controlled trialPregnancylawmedicineHumans030212 general & internal medicinePregnancy030219 obstetrics & reproductive medicinebiologyLacticaseibacillus rhamnosusObstetricsbusiness.industryMicrobiotaProbioticsObstetrics and GynecologyMiddle Agedbiology.organism_classificationmedicine.diseasePregnancy Trimester Firstmedicine.anatomical_structureVaginaVaginaFemaleBacterial vaginosisbusinessAmerican Journal of Obstetrics and Gynecology
researchProduct

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy

2005

In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 ±8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7x107 genomes/ml) treated with LAM [median (range): 44 (15–78) months]. A total of 50 patients (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of ther…

AdultLiver CirrhosisMaleHepatitis B virusCirrhosisHBV DNA Lamivudine Therapy suppression HBV diseasemedicine.disease_causeVirus ReplicationAntiviral AgentsVirusDrug Administration ScheduleDisease courseCohort StudiesOrthohepadnavirusmedicineHumansPharmacology (medical)AgedPharmacologyHepatitis B virusbiologyReverse-transcriptase inhibitorLamivudineMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologydigestive system diseasesInfectious DiseasesHepadnaviridaeLamivudineDNA ViralMutationFemalemedicine.drug
researchProduct